Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics

Area of Science:

• Biomedical Science
• Pharmacology
• Pathology

Background:

• The extracellular matrix (ECM) is implicated in over 50 chronic diseases, exhibiting diverse effects like tissue formation, degradation, or both.
• Pathologies affecting organs such as the lung, liver, kidney, skin, intestine, heart, and solid tumors involve significant ECM alterations.
• Understanding the common and distinct features of the fibroinflammatory axis in ECM is crucial for cross-disease therapeutic strategies.

Purpose of the Study:

• To explore the role of the extracellular matrix (ECM) in various chronic organ diseases.
• To identify common denominators and distinguishing factors in ECM's fibroinflammatory axis for drug development.
• To highlight advancements in tools and technologies for ECM-targeted drug discovery.

Main Methods:

• Review of state-of-the-art research presented at the 2nd Extracellular Matrix Pharmacology Congress.
• Discussion of ECM's role in liver, kidney, skin, intestine, musculoskeletal, lung, and solid tumor diseases.
• Identification of key ECM targets and enabling technologies for therapeutic development.

Main Results:

• The ECM is a central factor in numerous chronic pathologies, with common and unique fibroinflammatory characteristics across organs.
• Effective therapies for organ diseases require modulation of ECM composition to restore normal function.
• Advances in tools and technology are supporting the development of ECM-targeted drugs.

Conclusions:

• Modulating the extracellular matrix (ECM) presents a promising avenue for treating a wide range of chronic organ diseases.
• The 2nd Extracellular Matrix Pharmacology Congress facilitated knowledge exchange on ECM's role in disease and drug development.
• Further research into ECM targets and technologies is essential for advancing therapeutic interventions.